B
Bausch + Lomb Corporation (BLCO)
NYQ – Real Time Price. Currency in USD
15.37
-0.52 (-3.27%)
At close: Mar 27, 2026, 4:00 PM EDT
15.27
-0.10 (-0.65%)
After-hours: Mar 27, 2026, 6:28 PM EDT
Get all premium features to the best stock analysis tool
NYQ – Real Time Price. Currency in USD
15.37
-0.52 (-3.27%)
At close: Mar 27, 2026, 4:00 PM EDT
15.27
-0.10 (-0.65%)
After-hours: Mar 27, 2026, 6:28 PM EDT
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
| Name | Position |
|---|---|
| Dr. Yehia Hashad M.D., Ph.D. | Executive VP of Research & Development and Chief Medical officer |
| Mr. A. Robert D. Bailey | Executive VP & Chief Legal Officer |
| Mr. Alan Waterhouse CPFA, MBA | Executive VP and Chief Supply Chain & Operations Officer |
| Mr. Andrew J. Stewart | President of Global Pharmaceuticals & International Consumer |
| Mr. Brenton L. Saunders J.D. | CEO & Chairman |
| Mr. Frederick J. Munsch | Senior VP, Controller & Chief Accounting Officer |
| Mr. George Gadkowski | VP & Head of Investor Relations & Business Insights |
| Date | Type | Document |
|---|---|---|
| 2026-01-02 | 8-K | dp239510_8k.htm |
| 2025-12-22 | 8-K/A | blco-20251217.htm |
| 2025-12-17 | 8-K | d29805d8k.htm |
| 2025-12-12 | 8-K | dp238711_8k.htm |
| 2025-11-13 | 8-K | dp237254_8k.htm |
| 2025-10-29 | 10-Q | blco-20250930.htm |
| 2025-08-18 | 8-K | blco-20250814.htm |
| 2025-07-30 | 10-Q | blco-20250630.htm |
| 2025-07-23 | 8-K | dp231940_8k.htm |
| 2025-06-27 | 8-K | d932769d8k.htm |
| Mr. Jonathon L. Kellerman | Chief Compliance Officer |
| Mr. Osama A. Eldessouky | Executive VP & CFO |
| Mr. T.J. Crawford | Chief Communications Officer |